CMPX (STOCKS)
Compass Therapeutics, Inc. Common Stock
$5.190000
+0.020000 (+0.39%)
Prev close: $5.170000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Thomas J. Schuetz
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $934.66M
- Employees
- 35
- P/E (TTM)
- -11.92
- P/B (TTM)
- 4.68
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
9
Strong Buy
12
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.09 | $-0.09 | +0.0022 | +2.39% |
|
Sep 2025 (Q3)
|
$-0.08 | $-0.14 | +0.0603 | +42.98% |
|
Jun 2025 (Q2)
|
$-0.14 | $-0.12 | -0.0153 | -12.27% |
|
Mar 2025 (Q1)
|
$-0.12 | $-0.11 | -0.0068 | -6.01% |
Financial Statements
| Revenues | $0.00 |
| Operating Expenses | $72.84M |
| Depreciation and Amortization | $276.00K |
| Research and Development | $55.97M |
| Other Operating Expenses | $16.59M |
| Operating Income/Loss | -$72.84M |
| Income/Loss From Continuing Operations After Tax | -$66.49M |
| Income/Loss From Continuing Operations Before Tax | -$66.49M |
| Income Tax Expense/Benefit | $0.00 |
| Net Income/Loss | -$66.49M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$66.49M |
| Net Income/Loss Available To Common Stockholders, Basic | -$66.49M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.42 |
| Basic Average Shares | 157,695,000 |
| Assets | $219.59M |
| Current Assets | $209.82M |
| Noncurrent Assets | $9.77M |
| Fixed Assets | $102.00K |
| Other Non-current Assets | $9.67M |
| Liabilities | $22.80M |
| Current Liabilities | $13.97M |
| Accounts Payable | $1.59M |
| Other Current Liabilities | $12.38M |
| Noncurrent Liabilities | $8.83M |
| Equity | $196.79M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $196.79M |
| Liabilities And Equity | $219.59M |
| Net Cash Flow From Operating Activities | -$49.14M |
| Net Cash Flow From Operating Activities, Continuing | -$49.14M |
| Net Cash Flow From Investing Activities | -$93.31M |
| Net Cash Flow From Investing Activities, Continuing | -$93.31M |
| Net Cash Flow From Financing Activities | $129.61M |
| Net Cash Flow From Financing Activities, Continuing | $129.61M |
| Net Cash Flow | -$12.84M |
| Net Cash Flow, Continuing | -$12.84M |
| Comprehensive Income/Loss | -$66.42M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$66.42M |
| Other Comprehensive Income/Loss | -$66.42M |